Shopping Cart
- Remove All
- Your shopping cart is currently empty
Flanvotumab (IMC-20D7S) is a humanized monoclonal antibody targeting tyrosinase-related protein (TYRP1), exhibiting potent antitumor activity through natural killer-mediated and antibody-dependent cell-mediated cytotoxicity (ADCC).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $157 | In Stock | |
5 mg | $428 | In Stock | |
10 mg | $662 | In Stock | |
25 mg | $987 | In Stock | |
50 mg | $1,370 | In Stock |
Description | Flanvotumab (IMC-20D7S) is a humanized monoclonal antibody targeting tyrosinase-related protein (TYRP1), exhibiting potent antitumor activity through natural killer-mediated and antibody-dependent cell-mediated cytotoxicity (ADCC). |
In vitro | Flanvotumab is developed based on TA99, a mouse IgG2a monoclonal antibody against TYRP1. TA99 is positioned in subcutaneous melanoma xenografts and inhibits the growth of syngeneic tumors in preclinical models[1].The antitumor effect of TA99 relies on the presence of intact antibodies, Fc receptors, and natural killer (NK) cells[1]. |
Alias | IMC 20D7S, 20D7S |
Molecular Weight | 145.42 kDa |
Cas No. | 1188277-05-5 |
Storage | store at low temperature | store at -80°C | Shipping with blue ice. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.